PD-1 antibody

Org: Secarna Pharmaceuticals, Planegg-Martinsried, Department of Biomedicine, University of Basel, Department of Biomedicine, University of Basel, Switzerland,

Clinical trial

Neoadjuvant Toripalimab for Clinically Stage II-IIIB Resectable Non-small Cell Lung Cancer With EGFR Mutation and PD-L1 Positive Expression: a Prospective, Open-label, Multicenter, Single-arm Phase II Clinical Study

Status: Not yet recruiting, Estimated PCD: 2027-01-31

Clinical trial

The Effectiveness and Safety of Lenvatinib Combined Anti-programmed Death Immunotherapy for the Advanced Hepatocellular Carcinoma

Status: Completed, Estimated PCD: 2021-12-30

Clinical trial

A Single-arm, Phase II Clinical Study of Toripalimab Combined With Cryoablation for First-line Oligo-progression in Driver-negative Advanced NSCLC

Status: Not yet recruiting, Estimated PCD: 2025-11-20

Abstract

Real-world effectiveness and safety of PD-1 inhibitors combined with recombinant human endostatin and chemotherapy in refractory, recurrent/metastatic nasopharyngeal carcinoma.

Org: Zhejiang Cancer Hospital, Chinese Academy of Sciences, Hangzhou Yirui Pharmaceutical Technology,

Clinical trial

First-line Etoposide Combined With Platinum-based Chemotherapy Followed by Toripalimab Plus Anlotinib for the Maintenance of Extensive Stage Small Cell Carcinoma - A Randomized, Controlled, Multicenter Phase III Clinical Study

Status: Not yet recruiting, Estimated PCD: 2026-05-01

Clinical trial

A Prospective Single-arm Phase Ⅱ Study of Toripalimab Plus Neoadjuvant Chemotherapy Combined With Chemoradiotherapy for Locally Advanced Unresectable Esophageal Squamous Cell Carcinoma

Status: Active (not recruiting), Estimated PCD: 2024-12-20

Clinical trial

Prospective Safety Study of Sintilimab Combined With XELOX Plus Bevacizumab for Preoperative Neoadjuvant Therapy of CRLM Patients With pMMR/MSS Status

Status: Active (not recruiting), Estimated PCD: 2023-10-30

Clinical trial

Stereotactic Body Radiotherapy (SBRT) and Low-dose Radiotherapy (LDRT) Combined With Programmed Death 1 (PD-1) Antibody and Chemotherapy in Recurrent/Metastatic Nasopharyngeal Carcinoma: A Prospective, Single-arm, Phase II Clinical Trial

Status: Not yet recruiting, Estimated PCD: 2026-04-01

Clinical trial

A Comparative Study of Retrospective Outcomes Including Efficacy of Therapy Between Advanced Immunotherapy and Classical Immunochemotherapy in Relapsed/Refractory Lymphoma

Status: Active (not recruiting), Estimated PCD: 2025-12-31

Clinical trial

Stereotactic Body Radiotherapy With or Without Adjuvant Immunotherapy for Small Hepatocellular Carcinoma: An Open-label, Randomized, Phase II Trial

Status: Not yet recruiting, Estimated PCD: 2028-04-30

Clinical trial

Neoadjuvant Sintilimab Plus Anlotinib Therapy in IB-IIIB Resectable Non-small Cell Lung Cancer (PRIORITY): a Prospective Single Center, Open Label, Phase II Study

Status: Not yet recruiting, Estimated PCD: 2025-02-28

Clinical trial

A Single-center Phase II Study to Investigate the Immune Maintenance Therapy Pattern in Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma Who Have Achieved MPR After Neoadjuvant Immunotherapy Combined With Chemotherapy

Status: Recruiting, Estimated PCD: 2026-09-01

Clinical trial

Explore the Efficacy and Safety of Eribulin Combined With Sintilimab in the First-line Treatment of Unresectable Locally Advanced or Metastatic HER2-negative Breast Cancer

Status: Not yet recruiting, Estimated PCD: 2025-12-31

Clinical trial

A Phase 2, Open-label, Single Arm Study to Investigate the Safety and Efficiency of Golidocitinib in Combination With Sintilimab in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With PD-L1TPS ≥ 1%)

Status: Not yet recruiting, Estimated PCD: 2026-12-01

Clinical trial

A Single-arm, Phase II Clinical Trial to Treat Muscle-invasive Bladder Cancer With Induction Chemotherapy Plus Anti-PD-1 Therapy Followed by Radiotherapy Plus Concurrent Anti-PD-1 Therapy

Status: Recruiting, Estimated PCD: 2024-12-31

Clinical trial

Organoid Model Predictive of Response to Immunotherapies

Status: Recruiting, Estimated PCD: 2025-12-01

Clinical trial

A Prospective Randomized Controlled Study of Immune Checkpoint Maintenance Therapy After Radiotherapy and Chemotherapy for Locally Advanced Head And Neck Tumors Based on Peripheral Blood CD8Tex Detection in Peripheral Blood

Status: Recruiting, Estimated PCD: 2025-01-25

Clinical trial

Neoadjuvant Immunotherapy And Chemotherapy Followed By Concurrent Chemoradiation Or Organ Preservation Surgery In Locally Advanced Laryngeal Cancer And Hypopharyngeal Cancer

Status: Recruiting, Estimated PCD: 2027-09-01

Clinical trial

Modified Short-Course Radiation Combined With CAPOX and Tislelizumab for MSS Locally Advanced of Middle and Low Rectal Cancer (mRCAT): An Open-label, Single-arm, Prospective Multicenter Clinical Trial

Status: Recruiting, Estimated PCD: 2025-05-01

Clinical trial

A Prospective Phase II Trial of Short-course Radiotherapy Based Total Neoadjuvant Therapy Combined With PD-1 Inhibitor for Locally Advanced Rectal Cancer (TORCH）

Status: Recruiting, Estimated PCD: 2023-10-01

Clinical trial

A Phase III, Randomized, Double-blind, Placebo-controlled, Multi-center Study to Compare Toripalimab Injection (JS001) Combined With Standard Chemotherapy Versus Placebo Combined With Standard Chemotherapy in Treatment of Advanced or Metastatic Esophageal Squamous Cell Cancer (ESCC) Without Previous Systemic Chemotherapy

Status: Completed, Estimated PCD: 2021-03-22

Clinical trial

Phase II Trial of Neoadjuvant Immune-based Combinations in Patients Undergoing Nephrectomy for Locally Advanced ccRCC

Status: Recruiting, Estimated PCD: 2025-12-31

Clinical trial

The Clinical Value of Peripheral Blood T Lymphocyte PD-1 Expression and T Cell Subset Distribution in the Immunotherapy of Advanced Primary HCC Patients.

Status: Recruiting, Estimated PCD: 2024-06-30

Clinical trial

A Phase III Trial of Sintilimab Plus Lenvatinib in Hepatocellular Carcinoma With Portal Vein Tumor Thrombosis (PVTT) After Surgical Resection

Status: Not yet recruiting, Estimated PCD: 2024-11-01

Clinical trial

A Randomized Phase III Trial of Stereotactic Ablative Radiotherapy for the Comprehensive Treatment of 4-10 Oligometastatic Tumors (SABR-COMET 10)

Status: Active (not recruiting), Estimated PCD: 2029-01-01

Clinical trial

Efficacy and Safety of NSCLC Patients With or Without Adjuvant Immunotherapy Who Have Achieved Pathologic Complete Remission After Neoadjuvant Immunotherapy: A Prospective Real-World Study

Status: Recruiting, Estimated PCD: 2027-09-01

Clinical trial

Neoadjuvant Toripalimab and Paclitaxel/Cisplatin on Pathological Response in Oral Squamous Cell Carcinoma Patients: A Single-arm Phase I Trial

Status: Completed, Estimated PCD: 2021-04-12

Clinical trial

Efficacy and Safety of Modified Hepatic Artery Infusion Chemotherapy (TOMOX-HAIC) in Combination With Sintilimab and Bevacizumab Biosimilar for the First-line Treatment of Advanced Hepatocellular Carcinoma: a Prospective, Single-arm, Phase II Clinical Study

Status: Recruiting, Estimated PCD: 2024-12-31

Clinical trial

Efficacy and Safety of Disitamab Vedotin Combined With PD-1 in Posterior Line Therapy of Advanced HER2-low Expressing Gastric Cancer

Status: Recruiting, Estimated PCD: 2025-08-01

Clinical trial

Upfront Toripalimab Plus Axitinib Combined With Deferred Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma

Status: Not yet recruiting, Estimated PCD: 2026-03-01

Clinical trial

A Phase II Single Center Two Cohorts Trial of LM-108 in Combination With PD-1 Based Treatment for Patients With Recurrent or Metastatic Triple - Negative Breast Cancer

Status: Recruiting, Estimated PCD: 2026-04-01

Clinical trial

Efficacy and Safety of Toripalimab Plus Actinomycin-D as Fist-Line Treatment in Patients With Gestational Trophoblastic Neoplasia With FIGO Score 7: A Single-Arm, Multicenter, Phase II Trial

Status: Not yet recruiting, Estimated PCD: 2025-08-01

Clinical trial

Gastroparesis Outcome Longitudinal Database Enrolled Numerically

Status: Recruiting, Estimated PCD: 2026-01-01

Clinical trial

Toripalimab Maintenance After First-line Comprehensive Therapy for Locally Advanced Head and Neck Squamous Cell Carcinoma: a Single-arm, Phase II Study

Status: Not yet recruiting, Estimated PCD: 2026-02-01

Clinical trial

Hypofractionated Radiotherapy Combined With Chemotherapy and Toripalimab for Locally Recurrent Rectal Cancer: a Single-arm, Two-cohort, Phase II Trial (TORCH-R)

Status: Recruiting, Estimated PCD: 2024-12-01

Clinical trial

Induction Toripalimab and Chemotherapy in Locally Advanced Cervical Cancer Patients With High Risk of Recurrence: A Prospective, Single-Arm, Phase II Trial

Status: Recruiting, Estimated PCD: 2025-07-01

Clinical trial

A Randomized Phase III Trial of Stereotactic Ablative Radiotherapy for Patients With Up to 10 Oligometastases and a Synchronous Primary Tumor.

Status: Recruiting, Estimated PCD: 2029-04-01

Clinical trial

A Phase II Clinical Trial Evaluating the Efficacy and Safety of Sintilimab for Advanced Rare Cancers (SiARa Cancer Study) - Undifferentiated Pleomorphic Sarcoma (SiARa-UPS)

Status: Active (not recruiting), Estimated PCD: 2026-07-31

Clinical trial

Efficacy and Safety of Actinomycin-D With or Without Toripalimab as Fist-Line Treatment in Patients With Gestational Trophoblastic Neoplasia With FIGO Score 5-6: A Multicenter, Open-label, Randomized Controlled Trial

Status: Recruiting, Estimated PCD: 2025-08-01

Clinical trial

A Single-center Exploratory Clinical Study of Oral Inulin in Combination With Fruquintinib Plus Sintilimab as Third- or Further-line Treatment in Metastatic Colorectal Cancer

Status: Recruiting, Estimated PCD: 2024-12-01

Clinical trial

Perioperative Sintilimab Plus Bevacizumab Biosimilar and Transarterial Embolization, Hepatic Artery Infusion Chemotherapy (TACE-HAIC) for Hepatocellular Carcinoma Patients With Portal Vein Tumor Thrombus (PVTT): A Phase-2 Clinical Trial

Status: Recruiting, Estimated PCD: 2024-12-30

Clinical trial

Hepatic Arterial Infusion Chemotherapy Plus Toripalimab Versus Hepatic Arterial Infusion Chemotherapy Plus Sorafenib for Hepatocellular Carcinoma With Portal Vein Tumor Thrombus: a Non-comparative, Prospective, Randomized Trial

Status: Recruiting, Estimated PCD: 2023-12-20

Clinical trial

Neoadjuvant Therapy of SBRT Sequencial With Toripalimab and Chemotherapy in Resectable Stage II-III NSCLC Patients: A Multicenter, Openlabel, Randomized, Phase III Trial

Status: Not yet recruiting, Estimated PCD: 2027-06-01

Clinical trial

A Single-center, Single-arm, Phase II Clinical Study of Surufatinib Combined With Sintilimab and AG in First-line Therapy of Patients With Locally Advanced or Metastatic Pancreatic Cancer

Status: Recruiting, Estimated PCD: 2024-08-01

Clinical trial

A Phase Ib/II, Open-label, Dose-escalation and Dose-expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Antineoplastic Activity of CT-707 in Combination With Toripalimab and Gemcitabine in Advanced Pancreatic Cancer

Status: Recruiting, Estimated PCD: 2024-08-11

Clinical trial

Sequential bTAE-HAIC Combined With Lenvatinib and Sintilimab for Infiltrative Hepatocellular Carcinoma

Status: Recruiting, Estimated PCD: 2025-01-30

Clinical trial

Analyzing Clinical Outcomes and Genomic Data of American Indian Patient Population Treated With Immune Checkpoint Inhibitors for Various Cancers

Status: Active (not recruiting), Estimated PCD: 2024-07-01

Clinical trial

Evaluating the Efficacy of Allergen Immunotherapy in the Management of Allergic Asthma and Rhinitis

Status: Recruiting, Estimated PCD: 2023-12-30

Clinical trial

A Phase II Study of Lenvatinib Plus Sintilimab in Patients With Immune Checkpoint Inhibitor Previously Treated Advanced Liver Cancer

Status: Recruiting, Estimated PCD: 2025-08-20

Clinical trial

The Efficacy and Safety of Neoadjuvant Triprizumab and Radiotherapy in Operable Patients With Stage IIB-IIIA Non-small Cell Lung Cancer

Status: Recruiting, Estimated PCD: 2026-05-30

Clinical trial

Antitumor Activity of Toripalimab Combined With Radiotherapy in the Treatment of Oligometastatic Nasopharyngeal Carcinoma: A Single-arm, Multicenter Study

Status: Recruiting, Estimated PCD: 2025-12-31

Clinical trial

A Prospective, Single-arm, Phase II Clinical Trial to Evaluate the Efficacy and Safety of Tafolecimab and Sintilimab Combined With Chemotherapy in Patients With Advanced or Metastatic Driver Gene-negative Non-small Cell Lung Cancer After Failure of First-line Immunotherapy.

Status: Recruiting, Estimated PCD: 2027-05-30

Clinical trial

Anlotinib in Combination With Toripalimab and Chemotherapy for Neoadjuvant Treatment of Resectable Esophageal Squamous Cell Carcinoma: a Phase II Clinical Study

Status: Not yet recruiting, Estimated PCD: 2024-11-01

Clinical trial

Toripalimab With or Without Lenvatinib or Chemotherapy in First-Line Treatment of Advanced Biliary Tract Cancer

Status: Recruiting, Estimated PCD: 2025-03-06

Clinical trial

The Efficacy and Safety of Induction Chemotherapy and Toripalimab Followed by Chemoradiotherapy for Large-volume (Bulky) Local Advanced Non-small Cell Lung Cancer

Status: Recruiting, Estimated PCD: 2025-06-30

Clinical trial

Neoadjuvant PD-1 Antibody Plus Chemotherapy in Resectable Stage IIIA-N2 Non-Small-Cell Lung Cancer: A Randomized Phase II Study

Status: Terminated, Estimated PCD: 2022-09-30

Clinical trial

A Prospective Phase II Trial of Immunotherapy Combined With Short-course Radiotherapy in Early Low Rectal Cancer

Status: Recruiting, Estimated PCD: 2024-11-01

Clinical trial

Perioperative S-1 Plus Oxaliplatin Combined With Toripalimab or Toripalimab Monotherapy Versus S-1 Plus Oxaliplatin for Treatment of dMMR Locally Advanced Gastric or Esophagogastric Junction Adenocarcinoma: a Prospective, Multi-center, Randomized Controlled Study

Status: Recruiting, Estimated PCD: 2026-02-28

Clinical trial

Low-dose Radiation Therapy and Stereotactic Body Radiation Therapy Combined With PD-1 Inhibitor Sintilimab and Chemotherapy Versus PD-1 Inhibitor Combined With Chemotherapy as First-line Treatment for Patients With Advanced Squamous Cell Lung Cancer: A Randomized, Phase II Multicenter Clinical Trial

Status: Recruiting, Estimated PCD: 2027-02-28

Clinical trial

Exploratory Phase II Clinical Study of Toripalimab Plus Radiotherapy Versus Toripalimab Plus Chemotherapy for the Neoadjuvant Treatment of Operable Stage II-IIIA (N+) Non-small Cell Lung Cancer (NSCLC)

Status: Recruiting, Estimated PCD: 2024-12-01

Clinical trial

A Phase Ib/II Platform Trial of Newly Emerging Immunotherapy for Pancreatic Cancer Treatment

Status: Not yet recruiting, Estimated PCD: 2026-04-30

Clinical trial

Stop and go Strategy as First-line Treatment in Patients With Objective Response After Systematic Chemotherapy for Widely de Novo Metastatic Nasopharyngeal Carcinoma: A Phase II Trial

Status: Not yet recruiting, Estimated PCD: 2026-05-01

Clinical trial

Surufatinib and Toripalimab Combined With Chemotherapy for Second-line Treatment of Advanced RAS/BRAF Mutant and Microsatellite Stable Colorectal Cancer

Status: Recruiting, Estimated PCD: 2025-06-01

Clinical trial

A Single-arm Pilot Study of Tislelizumab Combined With Anlotinib in Patients With Advanced NSCLC With Driver-negative After Progression to Immunotherapy

Status: Not yet recruiting, Estimated PCD: 2028-07-01

Clinical trial

Efficacy and Safety Study of Oral All-trans Retinoic Acid Combined With Toripalimab in Patients With Inoperable Locally Advanced, Recurrent, or Metastatic Triple-negative Breast Cancer Who Had Failed Prior Second-line or Higher Standard Therapy.

Status: Not yet recruiting, Estimated PCD: 2026-04-30

Clinical trial

Toripalimab Combined With Neoadjuvant Chemoradiotherapy as First-line Treatment for Locally Advanced，High-Risk，MSS Rectal Cancer

Status: Recruiting, Estimated PCD: 2025-01-01

Clinical trial

A Prospective, Randomized, Controlled Phase II Trial of Regorafenib Alone or in Combination With High/Low-dose Radiotherapy Plus Toripalimab as Third-line Treatment in Patients With Metastatic Colorectal Cancer

Status: Recruiting, Estimated PCD: 2024-04-25

Clinical trial

Bronchial Artery Interventional Therapy and Sequential Radiotherapy in the Treatment of Non-resectable, Non-metastatic Central-type Squamous Lung Cancer

Status: Recruiting, Estimated PCD: 2025-02-01

Clinical trial

A Multi-Center Pilot Biomarker Study With Cardiopulmonary Monitoring in Lung Cancer Patients Receiving Combined Thoracic Radiotherapy and Immunotherapy

Status: Recruiting, Estimated PCD: 2028-04-19

Clinical trial

Sintilimab Combined With Anlotinib as Second- or Further-line Therapy for Extensive Disease Small Cell Lung Cancer: A Prospective, Single-arm, Phase II Study

Status: Completed, Estimated PCD: 2023-05-01

Clinical trial

Autologous Stem Cell Transplantation With CD34-Selected Peripheral Blood Stem Cells (PBSC) in Patients With Treatment Resistant Systemic Sclerosis (SSc)

Status: Recruiting, Estimated PCD: 2024-08-01

Clinical trial

A Phase II Study of Neoadjuvant Transcatheter Arterial Chemoembolization（TACE）Plus PD-1 Antibody (Tislelizumab) in the Locally Advanced Stomach Adenocarcinoma

Status: Recruiting, Estimated PCD: 2024-12-01

Clinical trial

Clinical Analysis of Naxitamab (hu3F8) in the Treatment of Pediatric High Risk or Refractory/ Relapsed Neuroblastoma

Status: Recruiting, Estimated PCD: 2024-12-31

Clinical trial

The Safety and Efficacy of PD-1 Antibody Combined With Pegylated Interferon-α Therapy to Promote the Clinical Cure in Nucleoside (Acid) Analogues-suppressed Chronic Hepatitis B Patients: A Protocol for the Prospective Pilot Study

Status: Recruiting, Estimated PCD: 2025-10-30

Clinical trial

First-line Anti-PD-1 Therapy Plus Chemotherapy With or Without Radiotherapy in Metastatic Esophageal Squamous Cell Carcinoma: A Phase II Multi-center, Randomized Trial (SCR-ESCC-01)

Status: Recruiting, Estimated PCD: 2026-01-01

Clinical trial

Clinical Study of Fruquintinib in Combination With Sintilimab as a First-line Therapy in Gastric Adenocarcinoma/Adenocarcinoma of Esophagogastric Junction

Status: Active (not recruiting), Estimated PCD: 2024-08-31

Clinical trial

Neoadjuvant Sintilimab or Combined With Chemotherapy for Stage III Driven Gene Mutation Negative Non-small Cell Lung Cancer

Status: Recruiting, Estimated PCD: 2023-09-15

Clinical trial

Phase II Study of Fruquintinib Combined With Sintilimab and TACE for Inoperable Primary Hepatocellular Carcinoma

Status: Recruiting, Estimated PCD: 2024-12-23

Clinical trial

JS001 Combined With Nab-paclitaxel and Cisplatin or Carboplatin as First-line Treatment for Unresectable or Advanced Small Cell Esophageal Carcinoma : a Prospective, Single Arm, Single Center, Phase II Clinical Trial

Status: Recruiting, Estimated PCD: 2024-11-17

Clinical trial

A Randomised, Open, Blank-controlled, Multi-centre Study of Anlotinib as Sequential Therapy in Patients With Unresectable NSCLC(Stage III) Who Have Not Progressed Following Definitive, Platinum-based, Concurrent Chemoradiation Therapy

Status: Completed, Estimated PCD: 2021-11-11

Clinical trial

The Neoantigen Targeting T Cells Suspension for Intravenous Infusion(Neo-T) in Treating Patients With Advanced Solid Tumor

Status: Recruiting, Estimated PCD: 2023-09-01

Clinical trial

Neoadjuvant PD-1 Blockade Combined With Chemotherapy Followed by Concurrent Immunoradiotherapy for Locally Advanced Anal Canal Squamous Carcinoma Patients

Status: , Estimated PCD: 2024-04-22

Clinical trial

A Single-arm, Open-label, Multicenter Phase II Clinical Trial to Evaluate the Efficacy and Safety of Disitamab Vedotin Combined With Toripalimab Sequential Chemotherapy as Neoadjuvant Treatment in Patients With HR-positive, HER2-low Breast Cancer

Status: Recruiting, Estimated PCD: 2025-06-01

Clinical trial

A Multicenter, Randomized, Double-blind, Placebo-controlled Clinical Trial of Anlotinib Capsules for the Treatment of Idiopathic Pulmonary Fibrosis (IPF)/Progressive Fibrosis-interstitial Lung Disease (PF-ILDs)

Status: Recruiting, Estimated PCD: 2024-07-01

Clinical trial

Radiotherapy Combined With Immune Checkpoint Inhibitors (ICIs) as Treatment for Locally Advanced Non-small-cell Lung Cancer After Failing Induction Immuno-chemotherapy: a Prospective, Real-world Cohort Study.

Status: Not yet recruiting, Estimated PCD: 2025-12-31

Clinical trial

Neoadjuvant Therapy With Toripalimab and JS004 Combined With Platinum-based Doublet Chemotherapy for Resectable or Potentially Resectable Stage III Non-small Cell Lung Cancer: A Randomised Controlled, Open-label, Phase 2 Trial

Status: Not yet recruiting, Estimated PCD: 2025-07-01

Clinical trial

PD-L1/PD-1 Inhibitors Plus Chemotherapy Versus Chemotherapy Alone for the Neoadjuvant Treatment of Limited-stage Small Cell Lung Cancer: an Open-label, Non-randomized Controlled, Phase II, Single-center Study

Status: Not yet recruiting, Estimated PCD: 2027-04-15

Clinical trial

A Phase II, Open-Label, Single-Arm, Prospective Clinical Study to Investigate the Efficacy and Safety of Tislelizumab Combined With Anlotinib as Maintenance Therapy Following Tislelizumab and Chemotherapy for Treatment Naïve Extensive Stage Small Cell Lung Cancer

Status: Recruiting, Estimated PCD: 2024-12-31

Clinical trial

An Open Label, Single-center Study on the Safety of Hepatic Arterial Infusion Chemotherapy Combined With Tislelizumab and Regorafenib in Patients With Advanced Treated Colorectal Liver Metastases

Status: Recruiting, Estimated PCD: 2024-07-30

Clinical trial

Neoadjuvant Chemoimmunotherapy With Tislelizumab, Albumin-bound Paclitaxel, and Cisplatin in Locally Advanced Oral/Oropharyngeal Squamous Cell Carcinoma: A Prospective, Multicenter, Single-arm Study

Status: Recruiting, Estimated PCD: 2024-06-30

Clinical trial

An Open, Randomized Phase III Study of Famitinib With Camrelizumab Plus Treatment of Physician's Choice (TPC) Versus Camrelizumab Plus TPC in The First-line Treatment of Immunomodulatory Locally Advanced or Metastatic Triple-negative Breast Cancer

Status: Recruiting, Estimated PCD: 2025-01-01

Clinical trial

The Safety and Efficacy of Endostar Combined With Toripalimab as Postoperative Adjuvant Therapy for Resectable Stage III-Oligometastatic Stage IV Cutaneous Melanoma: A Prospective, Single-arm, Open-label, Phase II Clinical Study

Status: Recruiting, Estimated PCD: 2024-08-01

Clinical trial

Perioperative Immunoagent (Tislelizumab) Plus Chemotherapy for Locally Advanced Resectable Thoracic Oesophageal Squamous Cell Carcinoma Trail:A Prospective Single-arm,Phase II Study (PILOT Trail)

Status: Recruiting, Estimated PCD: 2024-09-30

Clinical trial

Camrelizumab Combined With Apatinib Mesylate Tablets, Nab-paclitaxel and S-1 in the Treatment of Locally Advanced Gastric Cancer: an Multicenter, Open, Randomized, Controlled Clinical Study

Status: Active (not recruiting), Estimated PCD: 2022-07-22

Clinical trial

A Prospective, Single Arm Clinical Study to Evaluate Efficacy and Safety of Lenvatinib Combined With Tislelizumab in the First Line Treatment of Patients With Locally Advanced or Metastastic Fumarate Hydratase Deficient Renal Cell Carcinoma

Status: Recruiting, Estimated PCD: 2025-06-30

Clinical trial

Camrelizumab After Completion of Radiotherapy for Oligometastatic Nasopharyngeal Carcinoma: A Phase 2 Trial

Status: Recruiting, Estimated PCD: 2024-02-01

Clinical trial

Adjuvant Chemotherapy in Combination With Tislelizumab in Lymph Node-Positive Esophageal Squamous Cell Carcinoma

Status: Recruiting, Estimated PCD: 2025-06-30

Clinical trial

Neoadjuvant Sintilimab Plus Chemotherapy in EGFR-mutant Stage II-IIIB NSCLC: A Single-arm, Open-label Prospective Study

Status: Recruiting, Estimated PCD: 2024-06-01

Clinical trial

Study of Propranolol Hydrochloride in Combination With Sintilimab and Platinum-based Chemotherapy for Treatment of Advanced Non-small Cell Lung Cancer (BRIO)

Status: Not yet recruiting, Estimated PCD: 2025-08-31

Clinical trial

A Single-arm, Prospective Phase II Study of Camrelizumab Plus Apatinib and Chemotherapy as Neoadjuvant Therapy for Triple Negative Breast Cancer (TNBC)

Status: Recruiting, Estimated PCD: 2023-12-31

Clinical trial

A Phase II and III, Randomized, Multicenter Clinical Study: Toripalimab Plus Radiotherapy for Elderly Esophageal Cancer Patients Treated With Non-chemotherapy Strategy

Status: Recruiting, Estimated PCD: 2023-12-31

Clinical trial

Perioperative Chemotherapy Combined With PD-1 Inhibitor (Toripalimab) for Treatment of Epstein-Barr Virus-associated Locally Advanced Gastric or Esophagogastric Junction Adenocarcinoma: a Prospective, Multi-center, Phase II Study

Status: Not yet recruiting, Estimated PCD: 2026-07-28

Clinical trial

A Phase II Study to Evaluate the Efficacy and Safety of Cryoablation Combined With Sintilimab Plus Lenvatinib as First-line Treatment in Patients With Unresectable Advanced Intrahepatic Cholangiocarcinoma (ICC)

Status: Recruiting, Estimated PCD: 2025-12-30

Clinical trial

A Prospective Phase II Trial to Evaluate the Safety and Efficacy of Neoadjuvant Radiotherapy Combined With Immunotherapy for Locally Advanced Head and Neck Squamous Cell Carcinoma

Status: Not yet recruiting, Estimated PCD: 2024-05-20

Clinical trial

A Multicenter, Phase 3 Clinical Trial of Gemcitabine and Camrelizumab Plus Apatinib Versus Cisplatin in First-line Treatment of Recurrent/Metastatic Nasopharyngeal Carcinoma

Status: Recruiting, Estimated PCD: 2025-12-01

Clinical trial

A Prospective Phase II Study of Risk-stratification Based Bladder-sparing Modalities for Muscle-invasive Bladder Cancer After Chemotherapy Combined With PD-1 Antibody(Rebirth)

Status: Recruiting, Estimated PCD: 2023-12-01

Clinical trial

Efficacy and Safety of Postoperative Adjuvant Chemotherapy Combined With Camrelizumab for Patients With ⅡA -ⅢA Non-small Cell Lung Cancer：a Phase II , Single-arm Clinical Study

Status: Recruiting, Estimated PCD: 2026-04-01

Clinical trial

Evaluating the Impact of 18F-FDG-PET-CT on Risk Stratification and Treatment Adaptation for Patients With Muscle Invasive Bladder Cancer (EFFORT-MIBC): A Phase II Prospective Trial

Status: Recruiting, Estimated PCD: 2029-12-31

Clinical trial

A Phase Ib/II Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of JS015 Combination Therapy in Patients With Advanced Solid Tumors

Status: Not yet recruiting, Estimated PCD: 2025-11-30

Clinical trial

Perioperative Chemotherapy Plus PD-1 Antibody Compared With Perioperative Chemotherapy in the Locally Advanced Gastric Cancer: a Open-label, Phase 2 Randomised Controlled Trial

Status: Active (not recruiting), Estimated PCD: 2022-06-27

Clinical trial

Neoadjuvant Toripalimab Combined With Chemotherapy in Rare Mutations Stage IIB-IIIB NSCLC

Status: Recruiting, Estimated PCD: 2024-12-31

Clinical trial

Phase I Study of Whole Brain Low Dose Radiotherapy Combined With ICI and Intrathecal Chemotherapy for Treatment of Refractory Meningeal Metastasis of Lung Cancer

Status: Recruiting, Estimated PCD: 2026-05-01

Clinical trial

Neoadjuvant Chemotherapy Plus Toripalimab in Patients With Locoregionally Advanced Nasopharyngeal Carcinoma

Status: Recruiting, Estimated PCD: 2024-10-30

Clinical trial

A Single-arm Phase II Study to Evaluate Camrelizumab in Combination With Apatinib in Patients With Advanced Intrahepatic Cholangiocarcinoma

Status: Recruiting, Estimated PCD: 2024-07-01

Clinical trial

Phase II Study of Toripalimab Combined With Axitinib as Neoadjuvant Therapy in Patients With Non-metastatic Locally Advanced Nonmetastatic Clear Cell Renal Cell Carcinoma

Status: Completed, Estimated PCD: 2023-02-28

Clinical trial

The Value of Sintilimab Consolidation Therapy After Definitive Concurrent Chemoradiotherapy for Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma, an Open, Prospective, Single-arm Phase II Study

Status: Recruiting, Estimated PCD: 2023-08-04

Clinical trial

Vinorelbine, Carboplatin and Trastuzumab in Advanced Her-2 Positive Breast Cancer, a Phase 2 Study

Status: Active (not recruiting), Estimated PCD: 2023-12-01

Clinical trial

Gender Difference in sidE eFfects of ImmuNotherapy: a Possible Clue to Optimize cancEr tReatment

Status: Completed, Estimated PCD: 2023-02-28

Clinical trial

Combination Therapy of HAIC, Surufatinib and Tislelizumab for Unresectable or Metastatic Biliary Tract Cancer

Status: Not yet recruiting, Estimated PCD: 2024-06-01

Clinical trial

A Phase 1/1b Study of CHS-388 (Formerly Known as SRF388) in Patients With Advanced Solid Tumors

Status: Recruiting, Estimated PCD: 2025-12-01

Clinical trial

Sintilimab (PD-1 Antibody) and Chemoradiotherapy in Locoregionally-advanced Nasopharyngeal Carcinoma: a Randomized, Multicenter, Phase 3 Trial

Status: Active (not recruiting), Estimated PCD: 2023-02-28

Clinical trial

A Study to Evaluate the Efficacy and Safety of the Sintilimab Combined With Bevacizumab and Liver Protective Support Therapy in Child-Pugh B and/or ECOG PS 2 Unresectable Hepatocellular Carcinoma

Status: Recruiting, Estimated PCD: 2023-11-01

Clinical trial

Relation Between Tumor-draining Lymph Nodes Metastasis Pattern and Non-small Cell Lung Cancer Neoadjuvant Immunotherapy Effectiveness: A Retrospective Multi-institutional Cohort Analysis

Status: Completed, Estimated PCD: 2024-03-01

Clinical trial

Sintilimab After Concurrent Chemoradiotherapy in Elderly Patients With Unresectable Esophageal Squamous Cell Carcinoma: A Randomized, Multi-center Phase II Clinical Trial

Status: Not yet recruiting, Estimated PCD: 2026-06-01

Clinical trial

Hepatic Arterial Infusion Chemotherapy Plus Lenvatinib and Toripalimab for Advanced Hepatocellular Carcinoma： a Prospective, Single-arm Trial

Status: Completed, Estimated PCD: 2021-02-01

Clinical trial

A Phase II Study of L-BLP25 and Bevacizumab in Unresectable Stage IIIA and IIIB Non-Squamous Non-Small Cell Lung Cancer After Definitive Chemoradiation

Status: Completed, Estimated PCD: 2018-08-20

Clinical trial

Toripalimab After Radiotherapy Alone in Elderly Esophageal Squamous Cell Carcinoma: A Prospective Phase II Clinical Trial

Status: Not yet recruiting, Estimated PCD: 2024-04-30

Clinical trial

Neoadjuvant Toripalimab Plus Nimotuzumab in Primary Limited-Stage Oral Squamous Cell Carcinoma Prior to Radical Therapy：A Single-arm, Phase Ⅱ Study

Status: Not yet recruiting, Estimated PCD: 2024-09-30

Clinical trial

A Multicenter, Randomized Controlled Phase III Trial of Induction Plus Concurrent Chemoradiotherapy Plus Camrelizumab or Nimotuzumab Versus Induction Plus Concurrent Chemoradiotherapy in Locally Advanced Nasopharyngeal Carcinoma With Detectable EBV DNA After One Cycle GP Regime Neoadjuvant Chemotherapy

Status: Recruiting, Estimated PCD: 2025-01-01

Clinical trial

A Multi-center, Phase II Study to Evaluate Efficacy and Safety of Perioperative Chemotherapy With Fluorouracil, Leucovorin, Oxaliplatin, Docetaxel (FLOT) and Trastuzumab in Combination With Toripalimab in Patients With HER2 Positive Locally Advanced Gastric or Esophagogastric Junction Adenocarcinoma

Status: Recruiting, Estimated PCD: 2025-03-01

Clinical trial

A Phase II Study of Cryoablation Combined With Sintilimab Plus Lenvatinib in Patients With Immune Checkpoint Inhibitor Previously Treated Advanced Biliary Tract Cancer

Status: Recruiting, Estimated PCD: 2025-12-30

Clinical trial

A Prospective, Multicenter, Single-arm Clinical Study of the Efficacy and Safety of Toripalimab in Combination With Axitinib for Postoperative Adjuvant Therapy for Non-clear Renal Cell Carcinoma With High-risk Recurrence Factors

Status: Recruiting, Estimated PCD: 2026-12-30

Clinical trial

Prospective Single-arm Phase II Clinical Study of Fruquintinib Combined With Toripalimab and SRT in Neoadjuvant Therapy for Locally Advanced Rectal Cancer

Status: Recruiting, Estimated PCD: 2024-10-01

Clinical trial

An Open-labeled, Single-arm, Investigator-initiated Phase II Trial of Camrelizumab (Anti-PD-1 Antibody) in Combination With Apatinib and Eribulin in Patients With Advanced Triple-Negative Breast Cancer

Status: Active (not recruiting), Estimated PCD: 2022-11-30

Clinical trial

Phase III Randomized Multicentre Trial of Carboplatin + Liposomal Doxorubicin vs Carboplatin + Paclitaxel in Patients With Ovarian Cancer

Status: Active (not recruiting), Estimated PCD: 2023-12-01

Clinical trial

A Randomized Phase 2 Clinical Trial Evaluating Sintilimab and Chidamide in Combination With or Without IBI305 in Patients With Standard Treatment Failure of Advanced or Metastatic pMMR/MSS Colorectal Carcinoma

Status: Active (not recruiting), Estimated PCD: 2022-07-26

Clinical trial

A Randomized, Double-Blind, Multicenter, Phase III Study of Toripalimab(JS001) in Combination With Nab-Paclitaxel Versus Placebo Plus Nab-Paclitaxel for Patients With Metastatic or Recurrent Triple-Negative Breast Cancer With or Without Systemic Treatment (TORCHLIGHT)

Status: Active (not recruiting), Estimated PCD: 2023-12-31

Clinical trial

Weekly Versus Every 3 Week Carboplatin and Paclitaxel in Patients With Ovarian Cancer: a Phase III Randomized Multicenter Study

Status: Active (not recruiting), Estimated PCD: 2024-11-01

Clinical trial

A Prospective Phase Ib/II Trial of Radiotherapy Combined With Tyrosine Kinase Inhibitor and Immune Checkpoint Inhibitor in High-Risk Localized Soft Tissue Sarcoma (IRIS)

Status: Recruiting, Estimated PCD: 2024-07-31

Clinical trial

A Multi-center, Phase II Study to Evaluate Safety and Efficacy of Adjuvant Chemotherapy With Tegafur Gimeracil Oteracil Potassium Capsule Plus Oxaliplatin and Camrelizumab for Stage III Gastric Cancer (FOCUS-02)

Status: Active (not recruiting), Estimated PCD: 2023-09-09

Clinical trial

Surufatinib and Sintilimab in Combination With Capecitabine in Patients With Previously Treated Metastatic Adenocarcinoma of Small Intestine or Appendix Carcinoma : a Single-arm, a Single-center , Phase 2 Trial

Status: Recruiting, Estimated PCD: 2024-11-30

Clinical trial

LCH-IV, International Collaborative Treatment Protocol for Children and Adolescents With Langerhans Cell Histiocytosis

Status: Recruiting, Estimated PCD: 2025-07-01

Clinical trial

A Phase II Clinical Study of the Efficacy and Safety of Preoperative Sintilimab in Combination With Nab-paclitaxel and Cisplatin in Borderline Resectable Esophageal Squamous Carcinoma

Status: Completed, Estimated PCD: 2022-12-31

Clinical trial

A Phase Ib/II Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Initial Efficacy of Recombinant Humanized Anti-BTLA Monoclonal Antibody (JS004) Injection Combined With Toripalimab and With Standard Chemotherapy in Patients With Advanced Lung Cancer

Status: Recruiting, Estimated PCD: 2024-09-18

Clinical trial

Low-dose Radiotherapy Combined With Sintilimab and Temozolomide in Recurrent Glioblastoma: A Single-arm, Prospective Phase II Clinical Study

Status: Recruiting, Estimated PCD: 2027-12-30

Clinical trial

A Study to Evaluate the Efficacy and Safety of the Hepatic Arterial Infusion Chemotherapy(HAIC) Combined With Sintilimab and Bevacizumab Biosimilar in Unresectable Hepatocellular Carcinoma.

Status: Recruiting, Estimated PCD: 2022-01-10

Clinical trial

A Phase II Trial of Induction and Adjuvant Camrelizumab Combined With Chemoradiation in Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma

Status: Recruiting, Estimated PCD: 2025-01-01

Clinical trial

Concurrent Chemoradiotherapy Based of Cisplatin With or Without Sintilimab as First-line Therapy for Patients With Advanced Oral Cavity Squamous Cell Carcinoma :a Phase 2,Prospective, Open-label,Unicentral,Randomised Controlled Trial

Status: Recruiting, Estimated PCD: 2025-01-18

Clinical trial

IVIG Versus Plasmapheresis and Guillian Barrie Syndrome

Status: Completed, Estimated PCD: 2022-03-02

Clinical trial

A Novel Combination Therapeutic Strategy Aiming to Functional Cure for Chronic Hepatitis B Virus Infection (Sustained HBsAg Loss) (A)

Status: Not yet recruiting, Estimated PCD: 2025-12-31

Clinical trial

An Exploratory Study of the Efficacy and Safety of DCF Regimen Combined With Camrelizumab in the Treatment of Locally Advanced Esophageal Squamous Cell Carcinoma(ESCC)

Status: Recruiting, Estimated PCD: 2023-12-01

Clinical trial

PD-1 Inhibitor Plus Chemotherapy as Conversion Therapy in Unresectable Gastric Cancer (STARS-GC01): A Single-arm, Single-center, Prospective Clinical Study.

Status: Completed, Estimated PCD: 2023-05-06

Clinical trial

Efficacy of HAIC Combined With Lenvatinib and PD-1 Inhibitor in Infiltrative Hepatocellular Carcinoma: an Observational, Real-world Study

Status: Recruiting, Estimated PCD: 2024-12-30

Clinical trial

Induction Therapy for Locally Advanced Tumor With Immunotherapy Plus Chemotherapy vs. Chemoradiotherapy for Thoracic Squamous Esophageal Carcinoma

Status: Not yet recruiting, Estimated PCD: 2024-05-25

Clinical trial

A Phase 1b/2, Randomized, Open-Label Study Investigating the Efficacy and Safety of LBL-007 Plus Tislelizumab in Combination With Bevacizumab Plus Fluoropyrimidine Versus Bevacizumab Plus Fluoropyrimidine as Maintenance Therapy in Patients With Unresectable or Metastatic Microsatellite Stable/Mismatch Repair Proficient Colorectal Cancer

Status: Recruiting, Estimated PCD: 2028-04-01

Clinical trial

Long-course Concurrent Chemoradiotherapy Combined With Camrelizumab in the Neoadjuvant Treatment of Locally Advanced/Low Anus-preserving Rectal Cancer: a Phase II Single-arm Study.

Status: Not yet recruiting, Estimated PCD: 2026-08-16

Clinical trial

Efficacy and Safety of Toripalimab Adjuvant Therapy in High-risk Stage IA2-IB NSCLC With no Driver Alterations (EGFR or ALK) After Complete Resection: a Prospective, Single-arm Study

Status: Not yet recruiting, Estimated PCD: 2026-03-20

Clinical trial

A Phase 1b Study of Bispecific T Cell Redirection Antibodies in Combination With Checkpoint Inhibition for the Treatment of Participants With Relapsed or Refractory Multiple Myeloma

Status: Recruiting, Estimated PCD: 2024-09-21

Clinical trial

Neoadjuvant Chemoradiotherapy Followed by Sequential Immunotherapy for Thoracic Esophageal Squamous Cell Carcinoma

Status: , Estimated PCD: 2024-08-31

Clinical trial

Neoadjuvant Therapy With Toripalimab and JS004 Combined With Etoposide and Platinum Chemotherapy for Limited-stage Small Cell Lung Cancer : A Single-arm, Phase 2 Trial

Status: Recruiting, Estimated PCD: 2027-01-31

Clinical trial

Efficacy and Safety of Toripalimab After Concurrent Chemoradiotherapy in Elderly Patients With Esophageal Squamous Cell Carcinoma: a Multicenter, Randomized, Phase II Trial (EC-CRT-007)

Status: Recruiting, Estimated PCD: 2026-12-31

Clinical trial

The Effects of an Oncology Tailored Nutritional Intervention on the Bioavailability and Immune-activity of PD-1 Immune Checkpoint Inhibitors in Patients With Lung Cancer

Status: Recruiting, Estimated PCD: 2023-07-06

Clinical trial

A Prospective, Open-label, Multicenter Phase-II Trial to Evaluate the Efficacy and Safety of Zanubrutinib (BGB-3111), a BTK Inhibitor, Plus Tislelizumab (BGB-A317), a PD1 Inhibitor, for Treatment of Patients With Richter Transformation

Status: Active (not recruiting), Estimated PCD: 2023-12-01

Clinical trial

PD-1 Immune Checkpoint Inhibitor Combined With Intensity Modulated Radiation Therapy in the Treatment of Intermediate-risk Nasopharyngeal Carcinoma (T2-3N0 or T1-2N1 and EBV-DNA≤4000 Copy/ml),A Single-arm, Phase II Clinical Trial

Status: Recruiting, Estimated PCD: 2023-12-01

Clinical trial

Nab-Paclitaxel and Gemcitabine Plus Camrelizumab and Radiotherapy Versus Nab-Paclitaxel and Gemcitabine Alone for Locally Advanced Pancreatic Adenocarcinoma

Status: Recruiting, Estimated PCD: 2023-12-01

Clinical trial

Safety and Efficacy of Lenvatinib and Anti-PD1 Antibody Combined With Radiotherapy Neoadjuvant Treatment for Resectable Hepatocellular Carcinoma With PVTT,Prospective, Multicenter, Single-arm Study

Status: Recruiting, Estimated PCD: 2025-12-05

Clinical trial

A Phase II Study of Camrelizumab, Fluzoparib and Nab-paclitaxel in Neoadjuvant Therapy of Her-2 Negative Breast Cancer Patients With HRR Gene Mutation

Status: Recruiting, Estimated PCD: 2024-06-30

Clinical trial

A Prospective Randomized Phase II Trial of CAPOX and PD-1 Antibody Combined With or Without Radiotherapy for Microsatellite Stable Locally Advanced Rectal Cancer (TORCH-iTNT)

Status: Not yet recruiting, Estimated PCD: 2026-06-30

Clinical trial

Phase II Study Of Carboplatin Plus Paclitaxel Treatment Of Advanced Thymoma Or Thymic Carcinoma

Status: Completed, Estimated PCD: 2008-11-01

Clinical trial

Camrelizumab Combined With Induction Chemotherapy and Intensity Modulated Radiotherapy for the Treatment of Locally Advanced Nasopharyngeal Carcinoma:a Randomized, Multicenter, Phase II Trial

Status: Recruiting, Estimated PCD: 2025-04-06

Clinical trial

Prediction for pCR After Neoadjuvant Immunotherapy Combined With Chemotherapy Using Single-Cell RNA Sequencing in Patients With Locally Advanced Esophageal Squamous Cell Carcinoma (ESCC) : A Single-Arm Phase II Clinical Trial

Status: Completed, Estimated PCD: 2023-09-30

Clinical trial

Toripalimab With Paclitaxel and Cisplatin as Neoadjuvant Treatment for Esophageal Squamous Cell Carcinoma

Status: Recruiting, Estimated PCD: 2023-12-01

Clinical trial

Oncolytic Virus Plus PD-1 Inhibitor to Patients With Advanced Pancreatic Cancer

Status: Not yet recruiting, Estimated PCD: 2026-01-01

Clinical trial

Efficacy and Safety of Sintilimab and Bevacizumab Biosimilar Combined With Pegylated Liposomal Doxorubicin in Pretreated Metastatic Triple-negative Breast Cancer: a Single Arm Phase II Trial

Status: Recruiting, Estimated PCD: 2025-03-15

Clinical trial

A Single-arm, Non-randomized, Single-center Study to Evaluate Lenvatinib in Combination With Camrelizumab as First-Line Therapy in Patients With Advanced Hepatocellular Carcinoma

Status: Recruiting, Estimated PCD: 2024-08-01

Clinical trial

Perioperative Surufatinib Plus Sintilimab Combined With Chemotherapy in Locally Advanced Gastric and Gastroesophageal Junction Adenocarcinoma: the Phase 2 Solids-01 Trial

Status: Not yet recruiting, Estimated PCD: 2025-08-01

Clinical trial

A Multicenter, Open-label, Single-arm Study of Surufatinib in Combination With Tislelizumab for Second-line and Further Treatment of Metastatic Triple-negative Breast Cancer (TNBC)

Status: Not yet recruiting, Estimated PCD: 2024-08-01

Clinical trial

Pd1 Antibody Sintilimab ± Chemoradiotherapy for Locally Advanced Rectal Cancer

Status: Active (not recruiting), Estimated PCD: 2026-10-18

Clinical trial

A Phase Ib Study on Toripalimab Combined With Anlotinib and SBRT for Patients With Untreated Brain Metastases of Driven Gene-negative Non-small Cell Lung Cancer

Status: Recruiting, Estimated PCD: 2024-06-01

Clinical trial

A Phase II Trial of Tislelizumab in Combination With Sitravatinib for Recurrent/Metastatic Cervical Cancer After Platinum-Based Chemotherapy

Status: Withdrawn, Estimated PCD: 2023-06-01

Clinical trial

Neoadjuvant Anthracycline Followed by Toripalimab Combined With Nab-paclitaxel in Patients With Early Triple-negative Breast Cancer

Status: Active (not recruiting), Estimated PCD: 2022-09-28

Clinical trial

SHR-1210 Combined With Apatinib Mesylate in the Perioperative Therapy for Technically Resectable Hepatocellular Carcinoma

Status: Recruiting, Estimated PCD: 2024-06-30

Clinical trial

Toripalimab Combined With Definitive Chemoradiotherapy for Locally Advanced Cervical Squamous Cell Carcinoma Patients

Status: Recruiting, Estimated PCD: 2028-12-31

Clinical trial

Toripalimab Combined With Chemoradiotherapy Followed by Toripalimab Maintenance Therapy for High-risk Locally Advanced Cervical Cancer: the Phase II Single-arm TorCH -CC Study

Status: Recruiting, Estimated PCD: 2026-05-01

Clinical trial

Prospective, Single-arm, Phase II Study of Nab-paclitaxel Plus Carboplatin in Combination With Sintilimab for Neoadjuvant Therapy in Elderly, Locally Advanced, Resectable Esophageal Squamous Cell Carcinoma.

Status: Recruiting, Estimated PCD: 2026-05-01

Clinical trial

Phase II Trial of cTACE Plus Sintilimab for Treatment of Unresectable Intermediate-stage HCC With Beyond Up-to-seven Criteria

Status: Completed, Estimated PCD: 2022-05-01

Abstract

Temozolomide plus cisplatin versus toripalimab (anti-PD-1) as adjuvant therapy in resected mucosal melanoma.

Org: Key Laboratory of Carcinogenesis and Translational Research, Department of Genitourinary Oncology, Peking University Cancer Hospital & Institute, Department of Melanoma and Sarcoma,

Abstract

Final overall survival and biomarker analyses of CHOICE-01: A double-blind randomized phase 3 study of toripalimab versus placebo in combination chemotherapy for advanced NSCLC without EGFR/ALK mutations.

Org: State Key Laboratory of Molecular Oncology, National Clinical Research Center for Cancer, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing Chest Hospital, Capital Medical University, Beijing, China, Liaoning Cancer Hospital,

Abstract

Perioperative toripalimab + platinum-doublet chemotherapy vs chemotherapy in resectable stage II/III non-small cell lung cancer (NSCLC): Interim event-free survival (EFS) analysis of the phase III NEOTORCH study.

Org: Shanghai Chest Hospital, Hunan Cancer Hospital, Department of Pulmonary Medicine, Department of Thoracic Surgery and Oncology, Cancer Hospital of the University of Chinese Academy of Sciences,

Abstract

Perioperative PD-1 antibody toripalimab plus SOX or XELOX chemotherapy versus SOX or XELOX alone for locally advanced gastric or gastro-oesophageal junction cancer: Results from a prospective, randomized, open-label, phase II trial.

Org: State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center, The 6th Affiliated Hospital, Collaborative Innovation Center for Cancer Medicine,

Abstract

PD-1 blockade with sintilimab plus induction chemotherapy and concurrent chemoradiotherapy (IC-CCRT) versus IC-CCRT in locoregionally-advanced nasopharyngeal carcinoma (LANPC): A multicenter, phase 3, randomized controlled trial (CONTINUUM).

Org: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China, Guizhou Cancer Hospital, Guiyang, China, Affiliated Tumor Hospital of Guangxi Medical University, Guangxi, China, Department of Radiation Oncology, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China, Xijing Hospital, Xi'an, China,

Abstract

Uliledlimab and toripalimab combination therapy in treatment naive advanced NSCLC: Phase 1b/2 clinical trial results using CD73 as a potential predictive biomarker.

Org: Guangdong Lung Cancer Institute, I-Mab Biopharma US,

Abstract

Transcriptional metabolic profiling in young onset colorectal cancer (CRC) patients.

Org: University of Kentucky, Ohio State University Wexner Medical Center, Ohio State University James Cancer Hospital Department of Radiation Oncology, Roswell Park Comprehensive Cancer Center, Moffitt Cancer Center,

Abstract

A phase 1/2 study of the TORC1/2 inhibitor onatasertib combined with toripalimab in patients with advanced solid tumors.

Org: Antengene,

Abstract

Differential genomic and transcriptomic analysis of invasive lobular and ductal carcinomas.

Org: University of Texas MD Anderson Cancer Center, BostonGene Corporation, BostonGene, Corp.,

Abstract

Disitamab vedotin, a novel humanized anti-HER2 antibody-drug conjugate (ADC), combined with toripalimab in patients with locally advanced or metastatic urothelial carcinoma: An open-label phase 1b/2 study.

Org: Peking University Cancer Hospital and Institute (Beijing Cancer Hospital), Beijing, China, Peking University First Hospital, Affiliated Drum Tower hospital, Medical School of Nanjing University, Institute of Urology, Nanjing University, Nanjing, China,

Abstract

Response to programmed cell death protein 1 antibody in patients with Epstein-Barr virus-associated biliary tract cancer.

Org: Sun Yat-sen University Cancer Center Gansu Hospital, Chinese Academy of Sciences,

Abstract

A multicenter, single-arm, phase 2 study of surufatinib plus toripalimab for patients with advanced endometrial cancer.

Org: Cancer Hospital Chinese Academy of Medical Sciences, Beijing, China, West China Hospital, Sichuan University, Chengdu, China, The First Affiliated Hospital of Xiamen University, Xiamen, China, Sun Yat-sen Memorial Hospital of Sun Yat-sen University, Guangzhou, China, Beijing Cancer Hospital, Beijing, China,

Abstract

A multicenter, single-arm phase 2 study of surufatinib plus toripalimab for patients with locally advanced or metastatic radioactive iodine-refractory differentiated thyroid cancer.

Org: Fudan University Shanghai Cancer Center, The First Affiliated Hospital of Zhengzhou University, Department of Oncology, Jilin Cancer Hospital, Changchun, China, Jilin Cancer Hospital, HUTCHMED Limited,

Abstract

Neoadjuvant chemoimmunotherapy for the treatment of locally advanced laryngeal and hypopharyngeal squamous cell carcinoma: A single-arm phase 2 clinical trial.

Org: Sun Yat-sen University Cancer Center Gansu Hospital, Department of Radiation Oncology, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China,

Abstract

A phase Ib/II study to evaluate surufatinib combined with camrelizumab and chemotherapy in the second-line treatment of advanced colorectal cancer: Phase Ib results.

Org: Department of Oncology and Haematology, Division of Oncology, University Hospital of Modena, Modena, Italy, Jiangsu Cancer Hospital, Jiangsu Institute of Cancer Research, Nanjing, China,

Abstract

Efficacy and safety of combining PD-1 blockage and human papillomavirus vaccine for patients with relapsed/refractory advanced cervical cancer.

Org: Cancer Institute of Northern Jiangsu People's Hospital, Yangzhou, China,

Abstract

Deciphering primary and acquired immunotherapy resistance with whole genome and transcriptome analysis (WGTA).

Org: Princess Margaret Cancer Centre, University Health Network, University of Toronto, Department of Biostatistics, Yamaguchi University Graduate School of Medicine, Yamaguchi, Japan, Ontario Institute for Cancer Research, Toronto, ON, Canada,

Abstract

Are we ready for biomarker driven, radiation dose–adaptable de-escalation studies for HPV+ oropharyngeal cancer?

Org: Hematology and Medical Oncology, Universitätsklinikum Jena, Icahn School of Medicine at Mount Sinai/Tisch Cancer Institute, Department of Radiation Oncology, Sichuan Cancer Hospital & Institute, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China, Tisch Cancer Institute,

Abstract

Phase I/II combination study of tifcemalimab with toripalimab in patients with refractory extensive stage small cell lung cancer (ES-SCLC).

Org: Jilin Cancer Hospital, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China, Harbin Medical University Cancer Hospital, Henan Cancer Hospital, Yunnan Cancer Hospital, Kunming, Yunnan, China,

Abstract

Response-adapted therapy for locally advanced nasopharyngeal carcinoma based on clinical response and circulating Epstein-Barr virus DNA level post induction chemotherapy.

Org: Department of Radiation Oncology, Sichuan Cancer Hospital & Institute, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China, Fudan University Shanghai Cancer Center,

Abstract

Predicting role of circulating tumor DNA and blood-based tumor mutational burden in esophageal squamous cell carcinoma receiving chemoradiotherapy combined with toripalimab: Exploratory analyses from a phase II trial (EC-CRT-001).

Org: Sun Yat-sen University Cancer Center Gansu Hospital, Department of Radiation Oncology, Sichuan Cancer Hospital & Institute, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China,

Abstract

Final overall survival analysis of JUPITER-02: A phase 3 study of toripalimab versus placebo in combination with gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (NPC).

Org: Sun Yat-sen University Cancer Center Gansu Hospital, The Affiliated Cancer Hospital of Guangzhou Medical University, Fudan University Cancer Center, Cancer Center Union Hospital Tongji Medical College Huazhong University of Science and Technology, Affiliated Hospital of Guangdong Medical University,

Abstract

Induction therapy of toripalimab combined with docetaxel and cisplatin in locally advanced hypopharyngeal squamous cell carcinoma (HPSCC): A single-arm, phase II clinical trial.

Org: Peking Union Medical College Hospital, Academy of Medical Sciences & Peking Union Medical College, Beijing, China, Beijing InnoCare Pharma Tech, China National Biotec Group,

Abstract

Induction chemotherapy and toripalimab for larynx preservation in resectable locally advanced laryngeal/hypopharyngeal carcinoma: Preliminary results of INSIGHT study.

Org: Fudan University Shanghai Cancer Center, Department of Radiation Oncology, Sichuan Cancer Hospital & Institute, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China, Department of Head & Neck Tumors and Neuroendocrine Tumors, Fudan University Shanghai Cancer Center, Shanghai, China,

Abstract

A phase Ib/II study of GFH018 in combination with toripalimab in recurrent/metastatic nasopharyngeal carcinoma (R/M NPC).

Org: Sun Yat-sen University Cancer Center (China), Guangzhou, No, China National Biotec Group, Shanghai East Hospital, Tongji University, Shanghai, China, Tongji University School of Medicine,

Abstract

Analysis of overall survival (OS) and progression-free survival (PFS) in the phase 1b clinical trial of anti–PD-1 ab (toripalimab) plus intrahepatic injection of OrienX010 in stage IV melanoma with liver metastases.

Org: Key laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Melanoma and Sarcoma Oncology, Peking University Cancer Hospital & Institute, Department of Renal Cancer and Melanoma, Department of Ultrasound, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China,

Abstract

Endostatin in combination with PD-1 antibody plus chemotherapy as first-line regimen for EGFR/ALK-negative, advanced or metastatic non-small cell lung cancer: A real-world study.

Org: Department of Medical Oncology, The First Medical Center of PLA General Hospital, Beijing, China, Department of Medical Oncology, The Fifth Medical Center of Chinese PLA General Hospital, Beijing, China, Department of Medical Oncology,The First Medical Center of PLA General Hospital, Beijing, China, School of Medicine, Nankai University, Tianjin, China,

Abstract

A phase II clinical trial of chidamide in combination with toripalimab in patients with advanced soft tissue sarcoma.

Org: Department of Medical Melanoma and Sarcoma, Sun Yat-sen University Cancer Center Gansu Hospital, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China, Collaborative Innovation Center for Cancer Medicine, Melanoma and Sarcoma Medical Oncology Unit, Sun Yat-sen University Cancer Center, Guangzhou, China,

Abstract

Patterns of actionable biomarker testing in lung cancer patients: Disparity or an opportunity for improvement.

Org: Texas Tech Health Science Center, Lubbock, TX, Texas Tech University Health Sciences Center, El Paso,

Abstract

Effect of hypofractionated radiotherapy, PD-1 immunotherapy, and anti-angiogenic therapy on abscopal responses and the tumor microenvironment.

Org: Department of Radiation Oncology, Sichuan Cancer Hospital & Institute, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China, Tongji Medical College Huazhong University of Science and Technology, Hubei Cancer Hospital, Tongji Medical College, Huazhong University of Science and Technology, Huazhong University of Science and Technology Union Shenzhen Hospital, College of Biomedicine and Health,

Abstract

Assessing current diagnostic, staging, and treatment practices in community and academic centers for individuals with stage IB-IIIA non–small-cell lung cancer (NSCLC).

Org: Xaf Solutions, Pathologists Bio-Medical Laboratories, Luminis Health, Association of Community Cancer Centers (ACCC), Rockville, MD,

Abstract

Analysis of different color unmixing methods for cMET-PDL1-EGFR multiplex assay.

Org: Rochester Regional Health System, Santa Clara, CanSino Biologics, Tucson, AZ, Azidus Brasil,

Abstract

Anlotinib hydrochloride combined with tislelizumab, paclitaxel liposome, and nedaplatin regimen for preoperative neoadjuvant therapy of esophageal cancer: A single-arm, single-center, phase II exploratory clinical study.

Org: Department of Medical Oncology, The First Affiliated Hospital of Guangxi Medical University, Nanning, China, the First Affiliated Hospital of Guangxi Medical University, Guangxi, China, The First Affiliated Hospital of Guangxi Medical University, Nanning, China, Cardiothoracic surgery department, The First Affiliated Hospital of Guangxi Medical University, Nanning, China, Department of Thoracic Surgery, First Affiliated Hospital of Guangxi Medical University., Nanning, China,

Abstract

Development of a CCR8 monoclonal antibody to block CCR8 signaling and to abolish the immunosuppressive function of Treg for the treatment of cancers.

Org: Nanjing Immunophage Biotech Co., Ltd., Nanjing, China, Nanjing Immunophage Biotech Co., Ltd., Najing, China,

Abstract

A phase II study of toripalimab combined with gemcitabine-cisplatin as neoadjuvant therapy for patients with muscle-invasive bladder cancer (MIBC).

Org: Department of Urology, Zhujiang Hospital, Southern Medical University, Guangzhou, China, Department of Oncology, Zhujiang Hospital, Southern Medical University, Guangzhou, China,

Abstract

An analysis of National Cancer Data Base: Male breast cancer and overall survival.

Org: Creighton University Medical Center, Creighton University School of Medicine Phoenix Regional Campus, Department of Hematology Oncology, Kaiser Permanente, University of Nebraska Medical Center, Department of Hematology and Oncology, University Hospital Mannheim, Heidelberg University,

Abstract

TORCHLIGHT: A randomized, double-blind, phase III trial of toripalimab versus placebo, in combination with nab-paclitaxel(nab-P) for patients with metastatic or recurrent triple-negative breast cancer (TNBC).

Org: Department of oncology, the Fifth Medical Center of Chinese PLA General Hospital, Beijing, China, Department of Breast Medicine, Hunan Cancer Hospital, The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, China, Department of Breast Medicine, Cancer Hospital of China Medical University, Cancer Hospital of Dalian University of Technology, Liaoning Cancer Hospital and Institute, Shenyang, China, Harbin Medical University Cancer Hospital, Harbin, China, Department of Medical Oncology, The First Hospital of China Medical University, Shenyang, China,

Abstract

Assessing therapeutic window and dose selection of ADG126 (a masked anti-CTLA-4 SAFEbody): Integrating nonclinical and clinical data using mathematical modeling.

Org: Department of Clinical Medicine, Macquarie University, Sydney, Australia, One Clinical Research, Nedlands, Australia, Cabrini Research, Malvern, VIC, Australia, Sun Yat-Sen University Cancer Center, Guangdong, China, Adagene Inc., San Diego, CA,

Abstract

Sintilimab, SBRT and GM-CSF for metastatic NSCLC: A prospective, multicenter, phase II trial.

Org: Department of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China, Department of Thoracic Medicine, Hunan Cancer Hospital, The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, China, Tongji Hospital, Tongji Medical College Huazhong University of Science and Technology, Wuhan, China, Department of Oncology, Shengjing Hospital of China Medical University, Shenyang, China, Shanghai Lung Cancer Center, Shanghai Chest Hospital, Shanghai, China,

Abstract

Dysregulation of immune checkpoint proteins in patients with newly diagnosed early breast cancer undergoing neoadjuvant chemotherapy: A comparison between patients with triple negative breast cancer (TNBC) and non-TNBC.

Org: The Medical Oncology Centre of Rosebank, Johannesburg, South Africa, Department of Immunology, Faculty of Health Science, University of Pretoria, Pretoria, South Africa, University of Pretoria, Department of Immunology, Pretoria, South Africa, Netcare, City of Johannesburg, South Africa, Drs Gritzman and Thatcher Inc. Pathology Laboratory, City of Johannesburg, South Africa,

Abstract

GFH018, a small molecular inhibitor targeting TGF-βRI kinase, in patients with advanced solid tumors: final results of the phase I study.

Org: Department of Medical Oncology, Shanghai East Hospital, Tongji University School of Medicine, Shanghai, China, The First Affiliated Hospital of Bengbu Medical College, Bengbu, China, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, China, Department of Medical Oncology, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China, Sixth Affiliated Hospital of Sun Yat-Sen University, Guangdong, China,

Abstract

Updated safety and efficacy results from the phase I study of either LBL-007 (an anti-LAG-3 antibody) in combination with toripalimab (an anti-PD-1 antibody) or LBL-007 in combination with toripalimab and axitinib in patients with advanced melanoma.

Org: Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Renal Cancer and Melanoma, Peking University Cancer Hospital & Institute, Beijing, China, West China Hospital, Sichuan University, Chengdu, China, Department of Medical Oncology, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou, China, Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China, Hunan Cancer Hospital, the Affiliated Cancer Hospital of Xiangya Medical School, Central South University, Changsha, China,

Abstract

Effect of MDSC-targeted TFF2-MSA with PD-1 blockade therapy in advanced gastric cancer models.

Org: Columbia University Medical Center, Tonix Pharmaceuticals, Columbia University - Mailman School of Public Health,

Abstract

Effect of reducing the number of neoadjuvant chemoimmunotherapy cycles on clinical efficacy in locally advanced PD-L1 positive gastric cancer: A single center phase 2 study.

Org: Department of Immunology and Oncology, Clínica Universidad de Navarra, Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital, Henan Cancer Hospital, Department of Gastrointestinal Surgery, The Affiliated Nanchong Central Hospital of North Sichuan Medical College, Nanchong, China, Department of Surgical Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan,

Abstract

The safety and efficacy of donafenib combined with anti-PD-1 antibody as adjuvant therapy for patients (pts) with hepatocellular carcinoma (HCC): Updated results of a phase 2 study.

Org: Department of Hepatobiliary and Pancreatic Surgery, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China, The First Affiliated Hospital of USTC, Anhui Provincial Hospital, Hefei, China, Zhejiang University School of Medicine First Affiliated Hospital, Hangzhou, China, Hangzhou, China, Zhejiang, China,

Abstract

The efficacy and safety of toripalimab combined with sorafenib for unresectable hepatocellular carcinoma: An open-label, prospective, single-arm phase II study.

Org: Department of Liver Surgery and Transplantation, Liver Cancer Institute, Zhongshan Hospital, Fudan University; Key Laboratory of Carcinogenesis and Cancer Invasion (Fudan University), Ministry of Education, Shanghai, China, Liver Cancer Institute and Zhongshan Hospital, Fudan University, Shanghai, China, Zhongshan Hospital of Fudan University, Shanghai, China, Fudan University (Xiamen Branch), Key Laboratory of Carcinogenesis and Cancer Invasion (Ministry of Education), Fudan University,

Abstract

Comparison of first-line treatments for recurrent or metastatic nasopharyngeal carcinoma based on phase 3 randomized clinical trials.

Org: Department of Radiotherapy, Jiangsu Cancer Hospital, Nanjing, Jiangsu, China, Yunnan Cancer Hospital, Kunming, Yunnan, China, The Third Affiliated Hospital of Kunming Medical University, Kunming, Yunnan, China, Department of Head and Neck Surgery & Communication Sciences, Duke University School of Medicine, Durham, NC,

Abstract

Chemotherapy combined with anlotinib, toripalimab and stereotactic radiotherapy in oligo-metastatic nasopharyngeal carcinoma: A prospective, multicenter phase II clinical study.

Org: Department of Radiation Oncology, the First Affiliated Hospital of Guangxi Medical University, Nanning, China, Department of Medical Oncology, The First Affiliated Hospital of Guangxi Medical University, Nanning, China, Department of Radiation Oncology, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China, Department of Oncology, Affiliated Hospital of North Sichuan Medical College, Nanchong, China, Liuzhou Worker's Hospital, Liuzhou, China,

Abstract

A phase Ib study of porustobart (HBM4003), an anti-CTLA-4 heavy chain only monoclonal antibody, in combination with toripalimab in patients with hepatocellular carcinoma.

Org: Nanjing Tianyishan Hospital, NanFang Hospital of Southern Medical University, Haerbin Medical University Cancer Hospital, The First Affiliated Hospital of Henan University of Science and Technology, Hunan Cancer Hospital/the Affiliated Cancer Hospital of Xiangya School of Medicine, Changsha, China,

Product

SHR-1210 plus Apatinib

Product

Toripalimab + Chemotherapy

Product

Dato-DXd + pembrolizumab

Product

pembrolizumab + pemetrexed + platinum chemotherapy

Product

pembrolizumab + chemotherapy

Product

lifileucel and pembrolizumab